BiotechTube
Home/Pipeline/Linvoseltamab

Linvoseltamab

Relapsed/Refractory Multiple Myeloma

Phase 3Active

Key Facts

Indication
Relapsed/Refractory Multiple Myeloma
Phase
Phase 3
Status
Active
Company
Regeneron

About Regeneron

Regeneron Pharmaceuticals is a global biopharmaceutical leader with a mission to translate scientific innovation into life-changing medicines for patients with serious diseases. Founded in 1988, its achievements are anchored by blockbuster drugs like EYLEA® and Dupixent®, and a deep pipeline fueled by proprietary technologies like the VelocImmune® platform. The company's strategy combines a unique, vertically integrated R&D and manufacturing model with strategic collaborations, maintaining a fierce focus on long-term, science-driven growth.

View full company profile

Therapeutic Areas

OphthalmologyImmunology & InflammationOncology & HematologyRare DiseasesCardiovascular & Metabolic DiseasesNeuroscience

Other Relapsed/Refractory Multiple Myeloma Drugs

DrugCompanyPhase
Aplidin (plitidepsin)PharmaMarApproved (Conditional - AU)
TECVAYLI + DARZALEX FASPROJohnson and Johnson Innovative MedicineApproved
Blenrep (belantamab mafodotin)GSKPhase III
CAR T-Cell Therapy ProgramDr. Reddy's LaboratoriesDevelopment
HDP-101Heidelberg PharmaPhase I/IIa
inobrodib + Pd (InoPd)CellCentricPhase 1/2
CT053CARsgen TherapeuticsPhase Ib/II
CT059CARsgen TherapeuticsPhase I
P-BCMA-ALLO1Poseida TherapeuticsPhase 1
P-BCMA-101Poseida TherapeuticsPhase 1/2
ABBV-383AbbViePhase 1
bri-cel (BAY 2413334)BayerPhase I